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Background: Although survival of patients with metastatic breast cancer (MBC) has been significantly prolonged
over the past decade due to improvement of anti-cancer therapeutics, only a few patients survive for more than
10 years. It has not been determined which patients can have long-term survival with treatment.
Methods: To determine prognostic factors responsible for long-term survival, we retrospectively compared
clinicopathologic factors of patients with MBC who survived for 50 months or more after diagnosis with patients
who did not. Of 70 patients with MBC who received chemotherapy between November 2005 and September 2011,
23 patients who survived for 50 months or more after diagnosis and 28 patients who died within 50 months after
diagnosis were assessed for their clinicopathologic factors and outcomes.
Results: The proportion of patients with hormone receptor-positive (HR+) tumors was significantly higher and the
proportion of patients with triple negative tumors (TN) was lower in long-term survivors than in non-long-term
survivors (HR+: 87% versus 28.6%, P = 0.000037; TN: 13.1% versus 53.6%, P = 0.0028). Metastatic site, number of disease
sites, prior chemotherapeutic regimens and human epidermal growth factor receptor-2 (HER2) status did not differ
between the two groups. The proportion of patients who received metronomic regimens was significantly higher in
long-term survivors than in non-long-term survivors (65.2% versus 35.7%, P = 0.034) when the most effective regimen
among regimens that were received in metastatic settings was compared between the two groups. Overall response
rate was significantly higher (82.6% versus 17.9%, P <0.00001) and time to treatment failure after receiving the most
effective regimen was longer in long-term survivors than in non-long-term survivors (26 versus 5 months, P = 0.0001).
The number of chemotherapeutic regimens for breast cancer and that for MBC did not differ between the two groups.
Conclusions: Patients with luminal-type MBC who benefit at least once from chemotherapy including metronomic
regimens, or patients who continued to receive the most effective regimen for more than two years can be expected
to have long-term survival after diagnosis of MBC, regardless of the number of chemotherapeutic regimens they had
received.
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Breast cancer has a relatively favorable prognosis com-
pared with other cancers, such as lung, colon, ovarian
and pancreatic cancers. Approximately 80% of women
with primary breast cancer are expected to survive for at
least 10 years after the operation (mastectomy or breast-
conserving surgery) [1,2]. However, of patients who have* Correspondence: konbat@med.kagawa-u.ac.jp
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tially diagnosed with metastatic breast cancer (MBC),
only about 5% survive for more than 10 years [3,4].
Since women with MBC are unlikely to be cured from
the disease, palliative therapy is taken into account for
these patients for the purpose of prolongation of their
survival, with maintenance of quality of life. There have
been many clinical trials to assess the efficacy and safety
of anti-cancer cytotoxic agents in metastatic settings of
breast cancer [5-11]. In a first-line chemotherapy in this
setting, both anthracyclines and taxanes are expected tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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60% and survival of over two years, either by mono-
therapy or in combination with each other. In contrast,
the efficacy of chemotherapy is not satisfactory in the
second or later lines [12-19]. There are several possible
reasons for these results, such as resistance to drugs,
attenuated physical condition of the patients and less
availability of drugs to use because of prior drug usage.
Although the aim of treatment for MBC is control of
the disease and disease-related symptoms, treatment
can occasionally achieve progression-free or disease-free
long-term survival in patients with MBC [3,20,21]. Many
factors are thought to be responsible for determining
the survival term in MBC. Patient factors such as age,
menopausal status, performance status, disease-free in-
terval (DFI) and treatment that patients have received or
are receiving are associated with prognosis. Further,
tumor characteristics such as site of disease, number of
disease sites, tumor grade, hormone sensitivity, human
epidermal growth factor receptor-2 (HER2) status and
other biological characteristics are likely to be respon-
sible. However, the factors that are critical in predicting
a patient’s survival remains to be determined. If factors
involved in long-term survival of patients with MBC are
identified, they would be helpful for physicians to make
a decision regarding the choice of treatment strategy
and avoiding ineffective and harmful interventions in
daily clinical practice.
The aim of this study was to determine the factors re-
sponsible for long-term survival of patients with MBC.
We retrospectively compared clinicopathologic features
and clinical outcomes for patients with MBC who sur-
vived for a long period with those who did not survive
for a long period.
Methods
Patients
Data for patients with advanced or recurrent breast can-
cer who were treated with chemotherapeutic regimens
at Kagawa University Hospital between June 2006 and
September 2011 were retrospectively analyzed in this
study. The median age of the patients was 60 years (32
to 81 years), and the number of chemotherapeutic regi-
mens received for MBC until patients were treated with
the most effective regimen among those received in me-
tastatic settings was three [1-7]. The median follow-up
period was 30 months (1 to 68 months). The patients
were divided into two groups according to their survival
time after diagnosis of MBC: less than 50 months and
50 or more months. The former group, referred to as
non-long-term survivors, included 28 patients who died
within 50 months after diagnosis of MBC. There was no
patient who died from other causes, such as other dis-
eases, adverse events caused by treatment or accidentsin this group, indicating that all of the patients died of
MBC. The latter group, referred to as long-term sur-
vivors, included 23 patients who survived for at least
50 months after diagnosis, regardless of whether they
were receiving anti-cancer treatment. There were 19 pa-
tients who were alive at the time of analysis but had not
been followed up on for 50 months or more, and were
not included in the comparison. Clinicopathologic fac-
tors and outcomes of the patients are shown in Table 1.Evaluation of therapeutic efficacy
Tumor responses were assessed by physical examination
and computed tomography (CT), magnetic resonance im-
aging (MRI) or bone scan according to the Response
Evaluation Criteria in Solid Tumors (RECIST) [22] every
two to three months during treatment. Complete response
(CR) was defined as the absence of evidence of disease,
partial response (PR) was defined as a reduction in the
product of the two largest perpendicular diameters of the
target lesions by 50% or more, and progressive disease was
defined as an increase in tumor size by 25% or more or
the presence of a new lesion. Clinical response that did
not meet any definition described above was classified as
stable disease (SD). Clinical outcomes examined in this
study included time to treatment failure (TTF), defined as
the duration from initiation to discontinuation of treat-
ment, time to progression (TTP), defined as the duration
from initiation of treatment to disease progression or
death of any cause, overall survival (OS), defined as the
duration from initiation of treatment to death of any
cause, and objective response rate (ORR). Toxicity was
assessed according to the National Cancer Institute
Common Toxicity Criteria, version 3.0 [23].Statistical analysis
We used the Mann-Whitney U test or standard chi-
square procedures for comparison of the two groups. The
effects of baseline characteristics, clinical responses or
prognostic parameters on the risk of progression or death
were assessed using Kaplan-Meier survival analysis and
the log-rank test of significance. A 95% confidence interval
(CI) for the median of each variable was computed using
the method of Brookmeyer and Crowley [24]. We defined
P <0.05 as significant; all P values were two-sided. SPSS
statistical software system (SPSS Inc. Tokyo, Japan) was
used for all calculations.Ethical consideration
This research was in compliance with the guidelines of
the Ethics Committee at Kagawa University Hospital
and conformed to the provisions of the Declaration of
Helsinki in 1995.
Table 1 Comparison of clinicopathologic features of long-term survivors and non-long-term survivors
All patients Patients with OS >50 months Patient. with OS <50 months P value
Number 70 23 28
Age (years) 60 (32-82) 60 (37-82) 54.5 (32-81) 0.24
Disease-free interval (months) 36 (3-286) 60 (13-241) 13 (3-62) 0
Number of disease sites 2 (1-6) 2 (1-5) 2 (1-6) 0.56
Visceral lesion (%) 51.4 60.9 53.6 0.6
Tumor grade 2 (1-3) 1.5 (1-3) 3 (1-3) 0.07
Hormone-sensitive (%) 60 87 28.6 0
HER2-overexpressed (%) 18.2 22.2 25 0.84
Triple negative (%) 28.6 13.1 53.6 0
Prior A and T treatment (%) 35.7 47.8 35.7 0.39
Chemotherapy line 2 (1-5) 3 (1-5) 2 (1-4) 0.1
Chemotherapy line for MBC 1 (1-5) 2 (1-5) 1 (1-3) 0.03
Metronomic regimen (%) 45.7 65.2 35.7 0.03
Trastuzumab administration (%) 20 21.7 17.9 0.73
A and T, anthracycline and taxane; HER2, human epidermal growth factor receptor-2; MBC, metastatic breast cancer; OS, overall survival.
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Baseline characteristics of patients
A comparison of baseline clinicopathologic features bet-
ween the two groups showed that DFI was significantly
longer in long-term survivors than in non-long-term sur-
vivors (60 versus 13 months, P = 0.003, Table 1). The pro-
portion of luminal-type tumors was significantly higher
and the proportion of triple negative tumors was lower in
long-term survivors than in non-long-term survivors
(luminal-type: 87% versus 28.6%, P = 0.000037; triple
negative: 13.1% versus 53.6%, P = 0.0028). The proportion
of patients who received metronomic regimens as the
most effective regimen was significantly higher in long-
term survivors than in non-long-term survivors (65.2%
versus 35.7%, P = 0.034). Unexpectedly, the most effective
regimen was administered in later lines in long-term sur-
vivors compared to non-long-term survivors (two versus
one, P = 0.033), while the number of chemotherapy regi-
mens for breast cancer was not different between the twoTable 2 Comparison of outcomes and administered regimens
All patients Patients
ORR (%)* 44.9 82.6




OS from diagnosis of MBC 52 113
Number Of chemotherapy regimens* 1 (0-3) 1 (0-3)
Number of chemotherapy regimens for BC 3 (1-7) 4 (1-7)
Number of chemotherapy regimens for MBC 3 (1-7) 3 (1-7)
*Responses, outcomes or chemotherapy regimens after the most effective regimen
ORR, overall response rate; OS, overall survival; TTF, time to treatment failure; TTP, tgroups (three versus two, P = 0.1). Other factors including
age, number of disease sites, tumor grade, HER2 status
and prior anthracycline and taxane administration were
not different between the two groups.
Efficacy of treatment and clinical outcomes
A comparison of the clinical efficacy in the two groups
showed that both objective response rate (ORR) and
clinical benefit rate (CBR) were significantly higher in
long-term survivors than in non-long-term survivors
(ORR: 82.6% versus 17.9%, P <0.00001; CBR: 100% ver-
sus 35.7%, P <0.00001; Table 2). Of the 19 patients who
showed tumor responses in the long-term survivors
group, nine (26.1%) showed CR. In contrast, none of the
non-long-term survivors showed CR (data not shown).
To determine whether CR by the most effective regimen
leads to prolongation of survival, we compared clinical
outcomes of patients showing CR and patients not show-
ing CR in the long-term survivors group. Although all offor long-term survivors and non-long-term survivor










. BC, breast cancer; CBR, clinical benefit rate; MBC, metastatic breast cancer;
ime to progression.
Table 3 Comparison of clinical outcomes of patients
showing CR and those not showing CR
non-CR CR P value
TTF 20 34 0.22
TTP 30 51 0.29
OS 63 114 0.09
OS from diagnosis of MBC 95 103 0.78
CR, complete response; MBC, metastatic breast cancer; OS, overall survival;
TTF, time to treatment failure; TTP time to progression.
Kontani et al. World Journal of Surgical Oncology 2014, 12:344 Page 4 of 8
http://www.wjso.com/content/12/1/344the outcomes including TTF, TTP and OS were longer in
the CR group than in the non-CR group, there was no sta-
tistically significant difference between the two groups
(Table 3). These findings suggest that tumor responses in-
cluding long SD, PR and CR are needed in order to
achieve long-term survival of 50 months or more, and that
CR does not contribute to prolongation of survival. Fur-
thermore, administration of one chemotherapeutic regi-
men for more than two years and also clinical benefit (no
progression) lasting approximately three years obtained
using one regimen were essential for long-term survival in
MBC (TTF: 26 versus 5 months, P = 0.0003; TTP: 34 ver-
sus 5 months, P = 0.00013; Table 2 and Figures 1 and 2).
The median survival time after receiving the most ef-
fective regimen was significantly longer in long-term
survivors than in non-long-term survivors (68 versus
14 months, P <0.000001; Figure 3). The total number of
chemotherapeutic regimens for MBC, for breast cancer, or
after receiving the most effective regimen did not differ
between the two groups (Table 2). Furthermore, when
baseline characteristics were compared for patients who
survived for 60 months or more and patients who died
within 60 months after diagnosis of MBC as an explora-
tory analysis, the results were compatible with those de-
scribed above (Tables 4 and 5).Figure 1 Comparison of time to treatment failure (TTF) after the mos
survivors.Discussion
Although the aim of treatment for MBC is control of
the disease and disease-related symptoms, progression-
free or disease-free long-term survival is occasionally ob-
served following systemic treatment in patients with MBC
[3,20,21]. However, who is expected to be a long-term sur-
vivor, or what strategy is the best for long-term survival,
remains to be determined. In this study, we attempted to
determine what prognostic factors are responsible for
long-term survival by retrospectively comparing clinico-
pathologic features and clinical outcomes of patients with
MBC who had survived for 50 months or more after diag-
nosis of MBC with patients with MBC who had died
within 50 months after diagnosis. Of 70 patients with
MBC who had received chemotherapy at our hospital be-
tween November 2005 and September 2011, patients who
survived 50 months or more accounted for 38.6%, and pa-
tients who died within 50 months accounted for 40%. In
terms of baseline clinicopathologic features associated
with survival of the patients studied, the proportion of pa-
tients with longer DFI and the proportion of patients with
hormone-sensitive tumors were significantly higher in
long-term survivors, but the proportion of patients with
triple negative tumors was significantly lower in long-term
survivors (Table 1). Lower tumor grade seemed to show a
trend for long-term survival, although there was no statis-
tically significant difference between the two groups. In
contrast, the number of prior chemotherapeutic regimens
the patients had received was not lower in long-term sur-
vivors than in non-long-term survivors, and there was no
relationship of metastatic sites, number of disease sites,
prior chemotherapy regimens or chemotherapy line bet-
ween the two groups. These findings suggest that long-
term survival might be associated with slowly growing
luminal A-subtype tumors.t effective regimen in long-term survivors and non-long-term
Figure 2 Comparison of time to progression (TTP) after the most effective regimen in long-term survivors and non-long-term survivors.
PFS in the Figure 2 was changed into TTP.
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clines and taxanes are included in standard regimens be-
cause of abundant evidence from many clinical trials over
the past several decades showing significant reduction in
the risk of relapse or death from the disease [25-28]. In
contrast, there is no standard regimen recommended in
metastatic settings. In many cases of MBC, anthracyclines
and taxanes had already been administered in adjuvant
settings. Therefore, physicians often have difficulty in
choosing a regimen among agents for which clinical stu-
dies have demonstrated their feasibility. In cases of life-
threatening metastatic lesions or cases of rapidly growing
tumors, regimens that are expected to control lesions
quickly, such as taxanes in combination with either gemci-
tabine, capecitabine or bevacizumab, should be utilized
[28-33]. However, many patients show progression of dis-
ease during or after receiving these cytotoxic regimens,
even if favorable combinations are chosen. We previouslyFigure 3 Comparison of overall survival (OS) after the most effectivedemonstrated that long-term administration of one regi-
men was essential for favorable outcomes of treatment for
MBC [34]. To prolong the duration of treatment or the
TTF, chemotherapeutic regimens that are less toxic as well
as effective are considered. Metronomic chemotherapy is
defined as continuous or frequent treatment of low doses
of anticancer agents, and is usually used for palliative care
in patients who have been heavily pretreated with cyto-
toxic drugs, or patients who have poor performance status
[35]. Interestingly, metronomic chemotherapy used for
palliation has been reported to result in favorable tumor
responses and prolonged survival in some cases [36-39].
In this study, the proportion of patients who received a
metronomic regimen as the most effective regimen was
two thirds of long-term survivors (65.3%), which was
double that of non-long-term survivors (Table 1). Of 15
patients who were treated with metronomic regimens in
the long-term survivors group, nine (60%) received theregimen in long-term survivors and non-long-term survivors.
Table 4 Comparison of clinicopathologic features of long-term survivors (≥60 months) and non-long-term survivors
All patients Patients with OS >60 months Patients with OS <60 months P value
Number 70 17 28
Age (years) 60 (32-82) 60 (37-82) 56.5 (36-81) 0.86
Disease-free interval (months) 36 (3-286) 60 (13-241) 13 (3-62) 0.01
Number of disease sites 2 (1-6) 2 (1-3) 2 (1-6) 0.2
Visceral lesion (%) 51.4 52.9 50 0.91
Tumor grade 3 (1-3) 2 (1-3) 3 (1-3) 0.07
Hormone-sensitive (%) 60 88.2 28.6 <0.00002
HER2-overexpressed (%) 18.2 33.3 17.9 0.55
Triple negative (%) 28.6 5.9 60.7 0
Prior A and T treatment (%) 35.7 41.2 39.3 0.67
CT line 2 (1-5) 3 (1-5) 2 (1-4) 0.2
CT line for MBC 1 (1-5) 2 (1-5) 1 (1-3) 0.07
Metronomic regimen (%) 45.7 64.7 35.7 0.03
Trastuzumab administration (%) 21.3 23.5 16.7 0.41
A and T, anthracycline and taxane; CT, computed tomography; HER2, human epidermal growth factor receptor-2; MBC, metastatic breast cancer; OS, overall survival.
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ceived the regimen for two years but was continuing to re-
ceive the regimen at the time of analysis (data not shown).
Metronomic regimens may therefore have greatly contri-
buted to prolongation of the duration of treatment in this
group.
The proportion of patients who showed favorable tumor
responses to, or those who showed clinical benefit from,
the most effective regimen in long-term survivors was
three times (83%) and five times (100%) higher than in
non-long-term survivors, respectively (Table 2). The me-
dian TTF was more than two years and TTP was approxi-
mately three years in long-term survivors. These data
indicate that long SD or better tumor response (PR or CR)
to treatment for MBC at least once and continuation of
treatment with one regimen for more than two years areTable 5 Comparison of outcomes and administered regimens
survivors
All patients Patients with O
ORR (%)* 44.9 88.2




OS from diagnosis of MBC 52 113
Number of CT regimens* 1 (0-3) 1 (0-3)
Number of CT regimens for BC 3 (1-7) 5 (1-7)
Number of CT regimens for MBC 3 (1-7) 4 (1-7)
*Responses, outcomes or chemotherapy regimens after the most effective regimen
MBC, metastatic breast cancer; ORR, overall response rate; OS, overall survival; TTF,needed for long-term survival. TTP and OS after the most
effective regimen were significantly longer in long-term
survivors than in non-long-term survivors (Table 2,
Figures 2 and 3). However, in contrast to our expectation,
the number of chemotherapeutic regimens for breast can-
cer, for MBC or after receiving the most effective regimen
did not differ between the two groups. Furthermore, to ex-
clude the possibility that the prognostic factors described
above resulted from a relatively short observation period
in which the outcomes of the patients were compared, we
performed an exploratory analysis comparing prognostic
factors of patients who survived 60 months or more and
patients who died within 60 months after diagnosis of
MBC. As a result, all factors identified from baseline char-
acteristics and clinical outcomes of the patients by the
comparison did not differ from those that we compared atfor long-term survivors (≥60 months) and non-long-term










. BC, breast cancer; CBR, clinical benefit rate; CT, computed tomography;
time to treatment failure; TTP, time to progression.
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prior regimens for MBC (Tables 4 and 5).
Conclusions
Hormone-sensitive status is the most important factor
as a baseline characteristic responsible for long-term
survival. Furthermore, benefiting at least once from
chemotherapy and continuation of treatment with one
regimen for more than two years are needed for long-
term survival.
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